Therefore, a putative small molecule inhibitor for USP35 may help overcome resistance to therapy with PI3K α inhibitor for ER+ breast cancer with PIK3CA mutations or hyper-activation of the PI3K pathway in the future. The gene discussed is PIK3CA; the disease is breast carcinoma.